At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...